Standout Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alon... 2004 2026 2011 2018 5.1k
  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010)
    Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet
  2. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer (2004)
    David Cunningham, Yves Humblet et al. New England Journal of Medicine
  3. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer (2009)
    Eric Van Cutsem, Claus-Henning Köhne et al. New England Journal of Medicine
  4. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer (2008)
    Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology
  5. Everolimus for Advanced Pancreatic Neuroendocrine Tumors (2011)
    James C. Yao, Manisha H. Shah et al. New England Journal of Medicine
  6. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2012)
    Axel Grothey, Eric Van Cutsem et al. The Lancet
  7. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors (2011)
    Éric Raymond, Laëtitia Dahan et al. New England Journal of Medicine
  8. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial (2014)
    H. Wilke, Kei Muro et al. The Lancet Oncology
  9. Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer (2007)
    Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology
  10. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group (2006)
    Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology
  11. Gastric cancer (2016)
    Eric Van Cutsem, Xavier Sagaert et al. The Lancet
  12. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer (2019)
    Talia Golan, Pascal Hammel et al. New England Journal of Medicine
  13. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status (2011)
    Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology
  14. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer (2018)
    Michael J. Overman, Sara Lonardi et al. Journal of Clinical Oncology
  15. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (2008)
    Bernard Nordlinger, Halfdan Sørbye et al. The Lancet
  16. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer (2004)
    Al B. Benson, Deborah Schrag et al. Journal of Clinical Oncology
  17. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (2012)
    Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology
  18. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study (2020)
    Ghassan K. Abou‐Alfa, Vaibhav Sahai et al. The Lancet Oncology
  19. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial (2009)
    Arnaud Roth, Sabine Tejpar et al. Journal of Clinical Oncology
  20. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014)
    Eric Van Cutsem, Andrés Cervantes et al. Annals of Oncology
  21. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial (2013)
    Bernard Nordlinger, Halfdan Sørbye et al. The Lancet Oncology
  22. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study (2011)
    Atsushi Ohtsu, Manish A. Shah et al. Journal of Clinical Oncology
  23. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial (2012)
    Jaafar Bennouna, Javier Sastre et al. The Lancet Oncology
  24. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (1998)
    Philippe Rougier, Eric Van Cutsem et al. The Lancet
  25. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011)
    Marianne Pavel, John D. Hainsworth et al. The Lancet
  26. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer (2010)
    Marc Peeters, Timothy Price et al. Journal of Clinical Oncology
  27. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab (2007)
    Wendy De Roock, Hubert Piessevaux et al. Annals of Oncology
  28. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study (2015)
    Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology
  29. Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer (2004)
    Eric Van Cutsem, Helgi van de Velde et al. Journal of Clinical Oncology
  30. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer (2015)
    Eric Van Cutsem, Heinz‐Josef Lenz et al. Journal of Clinical Oncology
  31. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab (2010)
    Wendy De Roock, Derek J. Jonker et al. JAMA
  32. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials (2017)
    Dirk Arnold, B. Lueza et al. Annals of Oncology
  33. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer (2011)
    Daniel G. Haller, Josep Tabernero et al. Journal of Clinical Oncology
  34. Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer (2009)
    Eric Van Cutsem, Walter L. Vervenne et al. Journal of Clinical Oncology
  35. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954 (2010)
    Christoph Schuhmacher, Stephan Gretschel et al. Journal of Clinical Oncology
  36. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer (2016)
    Sabine Tejpar, Sebastian Stintzing et al. JAMA Oncology
  37. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials (2012)
    Carsten Bokemeyer, Eric Van Cutsem et al. European Journal of Cancer
  38. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer (2021)
    Yelena Y. Janjigian, Akihito Kawazoe et al. Nature
  39. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer (2014)
    Eric Van Cutsem, Yung‐Jue Bang et al. Gastric Cancer
  40. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017)
    Theo J. M. Ruers, Frits van Coevorden et al. JNCI Journal of the National Cancer Institute
  41. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study (2017)
    Peter Thuss‐Patience, Manish A. Shah et al. The Lancet Oncology
  42. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study (2013)
    Atsushi Ohtsu, Jaffer A. Ajani et al. Journal of Clinical Oncology
  43. Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus (2015)
    René Adam, Aimery de Gramont et al. Cancer Treatment Reviews
  44. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 (2018)
    Yu Jeong Bang, Eduardo Yañez Ruiz et al. Annals of Oncology
  45. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study (2021)
    Josep Tabernero, Axel Grothey et al. Journal of Clinical Oncology
  46. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023)
    Kohei Shitara, Florian Lordick et al. The Lancet
  47. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023)
    Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet
  48. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer (2023)
    Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine
  49. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial (2023)
    Zev A. Wainberg, Davide Melisi et al. The Lancet
  50. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 (2022)
    Thierry André, Sara Lonardi et al. Annals of Oncology
  51. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study (2023)
    Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology
  52. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial (2025)
    Scott Kopetz, Takayuki Yoshino et al. Nature Medicine

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 221 standout
Sub-graph 1 of 18

Citing Papers

Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization
2025 Standout
Pancreatic cancer: Advances and challenges
2023 Standout
25 intermediate papers

Works of Eric Van Cutsem being referenced

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
2022
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
2019 Standout
and 57 more

Author Peers

Author Last Decade Papers Cites
Eric Van Cutsem 68215 35069 20117 1.2k 92.5k
David Cunningham 41215 30035 24021 1.2k 76.0k
Murray F. Brennan 38013 42545 30995 951 79.5k
Mithat Gönen 25916 18942 20330 769 58.9k
Daniel J. Sargent 37110 17777 12411 474 57.2k
Josep Tabernero 33324 14187 7861 1.1k 49.1k
Jaap Verweij 27869 21972 8677 619 54.4k
Ralph H. Hruban 61469 13894 30683 910 91.5k
Charles J. Yeo 41653 17062 28533 563 55.1k
David S. Klimstra 33496 10129 18697 486 47.2k
Lawrence H. Schwartz 20632 20087 8158 386 50.1k

All Works

Loading papers...

Rankless by CCL
2026